Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity. 
Asian Activities Report for October 27, 2011 includes: C @ Limited (ASX:CEO) has signed an agreement to acquire eight highly prospective Mongolian coal licences for US$7.8 millions; African Iron Limited (ASX:AKI) announces a 267% increase in the JORC hematite mineral resource to 121 million tonnes at its 92% owned Mayoko Iron Ore Project in Congo; ENK Plc (ASX:ENK) announces the first nickel production from its pilot plant located 250 km north of Manila in the Philippines; Solagran Limited (ASX:SLA) recently visited an Asian country where a poultry trial was conducted in collaboration with a government body in the field of poultry production and disease management.
The Directors of Solagran Limited (ASX: SLA; PNK: SOGRF) are pleased to provide an update in relation to the production and marketing of Ropren(R) in Russia.
The Directors of Solagran Limited (ASX: SLA)(PNK: SOGRF) are pleased to announce details of the path forward that the Board has adopted for the marketing of Ropren in Russia, and at the same time advise the market that Solagran has terminated discussions with the Menarini Group in relation to a potential strategic partnership.
Australian Biotech Solagran Limited today announced the opening in Russia of the world's first commercial scale plant for the isolation and extraction of pharmaceutical grade polyprenols.
The Directors of Solagran Limited (ASX: SLA)(PNK: SOGRF) are pleased to announce the formal opening of the SibEX production facility in Tomsk in south western Siberia. SibEX is now an 85 percent owned subsidiary of Solagran Limited.
On 28 February 2008, Solagran Limited (ASX: SLA)(PNK: SOGRF) announced to the ASX that Russian regulatory authorities were expected to release its new prescription pharmaceutical Ropren for sale in the Russian market within 1 to 1.5 months. The Directors of Solagran are pleased to announce that this final administrative formality was completed sooner than expected and the official release to market has now been received.
Further to Solagran Limited's (ASX: SLA) ASX announcement of 20 February 2008 in which it was stated that the award of Manufacturing Licences for both the prescription pharmaceutical Ropren and its active ingredient Bioeffective R was imminent, the Directors of Solagran are pleased to announce that the Ministry of Health of the Russian Federation has now issued these licences.
The Directors of Solagran Limited (ASX: SLA) are pleased to announce the achievement of the last significant milestone in the process of obtaining Manufacturing Licences for both the prescription pharmaceutical Ropren and its active ingredient Bioeffective R.
The Directors of Solagran Limited (ASX: SLA) are pleased to provide a summary of the results of the Ropren clinical trials conducted at the Skvortsova-Stepanova psychiatric hospital in 2006-07 with serious and critically ill, drug addicted chronic alcoholics. These very challenging trials constitute a key element in Solagran's ongoing research effort in both Australia and Russia to demonstrate the multi-faceted nature of Ropren and specifically its efficacy in the prevention and treatment of a range of neurodegenerative disorders.
Further to the recent announcement of the visit by Victoria Gorbacheva, MD PhD, the Head of Business Development in Russia of Berlin-Chemie/Menarini Pharma GmbH, the Directors of Solagran Limited (ASX: SLA) are very pleased to announce the intended path forward following a week of intense and productive meetings.
